Actos Side Effect Lawsuits
Written by Faith Anderson on February 21, 2012
Actos and Bladder Cancer Side Effects
Actos (pioglitazone) was introduced to the market in 1999 and has since been prescribed to patients struggling with type 2 diabetes. Unfortunately, recent Actos FDA warnings have notified patients and healthcare providers that use of the diabetes drug for more than one year may be linked to an increased risk of bladder cancer side effects. In response to this side effect risk, Takeda’s parent company, Takeda Pharmaceuticals Co. Ltd., halted sales of Actos in France and Germany last year. Although the FDA issued an Actos bladder cancer side effect warning in 2010, Actos sales were allowed to continue.
Takeda Defends Potentially Dangerous Diabetes Medication
After the FDA approved Actos in 1999, Takeda co-promoted the drug in the U.S. with Eli Lilly & Co. until 2006, when the companies’ agreement ended and Takeda took over responsibility for the drug’s marketing. As Takeda says, “Takeda is confident in the therapeutic benefits of Actos and its importance as a treatment for type 2 diabetes. As a science and evidence-based company, Takeda firmly stands behind the substantial data available confirming the positive risk/benefit profile of Actos, which includes twelve years of clinical and patient experience with the product.”
Thousands of Actos Side Effect Lawsuits Expected to Be Filed
The consolidated Actos lawsuits claim that researchers have found a connection between bladder cancer side effects and the use of Actos for more than one year. The suits also accuse Takeda of concealing its knowledge of this cancer risk and failing to adequately warn consumers and healthcare providers. Thousands of other Actos lawsuits are expected to be heard in California and Illinois state courts on behalf of affected Actos patients.